Premium
Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC‐3 prostate cancer cells
Author(s) -
Dutta Rana,
Sens Donald A.,
Somji Seema,
Sens Mary Ann,
Garrett Scott H.
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10097
Subject(s) - transfection , cell culture , prostate cancer , microbiology and biotechnology , biology , cell growth , cancer research , gene expression , cancer cell , growth inhibition , metallothionein , prostate , cell , gene isoform , cancer , gene , biochemistry , genetics
BACKGROUND The third isoform of metallothionein (MT‐3) is overexpressed in prostate cancers and PIN lesions. The expression of MT‐3 is highly variable but appears to correlate to Gleason score. The goal of the present study was to determine the effect of MT‐3 overexpression on the growth of the PC‐3 prostate cancer cell line. METHODS PC‐3 cells were stably transfected with either the MT‐3 or MT‐1E gene. Cell growth was determined by counting DAPI‐stained nuclei, drug resistance by the colony formation assay, MT mRNA expression by reverse transcriptase‐polymerase chain reaction, and MT protein by immunoblot. RESULTS PC‐3 cells that overexpress the MT‐3 gene are growth inhibited compared with either untransfected cells, cells with blank vector, or cells with similar overexpression of the MT‐1E gene. Furthermore, increased chemotherapeutic drug resistance occurred in PC‐3 clones derived from MT‐3– and MT‐1E–transfected cells. CONCLUSION The overexpression of MT‐3 can influence the growth and chemotherapeutic drug resistance of the PC‐3 prostate cancer cell line. Prostate 52: 89–97, 2002. © 2002 Wiley‐Liss, Inc.